WuXi’s AAALAC-accredited DMPK Unit is a full-scale in vitro ADME and in vivo PK service provider. We are capable of running high throughput screens using early ADME assays and subsequently optimizing lead compounds through synergistic integration with the medicinal chemistry, pharmacology and bioanalytical units. Preclinical drug candidates can be further developed in tandem with the toxicology unit providing a seamless process culminating in a submission-ready IND accepted around the world. Since 2012 we have completed a package or part of a package for 32 INDs and 2 NDAs spanning both small and large molecule therapeutics.
In October 2014, WuXi AppTec acquired XenoBiotic Laboratories, Inc. (XBL) which has increased our late-stage capabilities as well as our international footprint by expanding our operations into Plainsboro, NJ, USA. For the convenience of our Western clients, WuXi now offers discovery stage studies at the Plainsboro, NJ site in addition to Shanghai or its suburb Suzhou (large animal PK). Additionally XBL in Plainsboro, NJ offers descriptive ADME and clinical Met ID studies along with quantitative whole body autoradiography (QWBA).
In Vitro ADME.
Early and definitive ADME services. ( Learn More)
In Vivo PK.
Exploratory or IND-enabling animal studies. (Learn More)
In Vivo PD.
Rodent in vivo pharmacology models.
Non human primate in vivo pharmacology models. (Learn More)
In vitro/in vivo Met ID studies. (Learn More)